Genmab — Januar 2018
-
Yderst interessant fremlæggelse på fredag af Chen. Selv om 15-23% ikke lyder af meget er det på niveau med virkningen på de øvrige I/O drugs of ydermere har han måske mere i ærmet med denne formulering: Further study revealed that control of tumors by triple blockade of CD38, PD-1, and CTLA-4 depended on improved functionality of CD4+/CD8+ TILs, which were reactivated by enriched CD103+ dendritic cells in the tumor microenvironment. Mon det er opskriften på "cure" eller kontrol over cancer ?
-
Jeg har kun set at AQR er gået ned på 1.4 %, fra 1.51% eller hvad det nu præcis var

-
Du har da fuldstændig ret OHW - ved ikke lige hvordan det var kommet i hovedet på mig

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind